Retension Pharmaceuticals, Inc. (RTSN): CAO Robert Wong appointed

Events in this filing

Item 5.02 as filed

Item 5.02 - Departure of Directors or
Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Appointment of Chief Accounting Officer
On October 21, 2026, the Board
of Directors of Retension Pharmaceuticals, Inc. (the “Company” or “Retension”) appointed Robert Wong as Vice President,
Chief Accounting Officer (Principal Accounting Officer) of the Company, effective as of November 2, 2026 (the “Commencement Date”).
Mr. Wong, age 60, brings 30
years of management and controllership experience to the Company, most recently serving as Vice President of Accounting of The Save Mart
Companies, one of the West Coast’s largest regional, full-service grocery chains, where he managed a team responsible for the company’s
accounting, finance, tax and treasury. Prior to that, he served as Vice President and Chief Accounting Officer of at Cytokinetics, Inc.
(NASDAQ: CYTK), a biopharmaceutical company, from 2019 to 2024 and from 1996 to 2019, served in roles of increasing responsibility in
accounting and finance, culminating in serving as Controller and Chief Accounting Officer, of Genentech, Inc., a biotechnology company
that became a wholly owned subsidiary of Roche Holding in 2009. Mr. Wong began his career as an audit manager at Ernst & Young LLP.
He received his Bachelor of Science in Business Administration from the University of California, Berkeley and is a certified public accountant.
There is no arrangement or
understanding between Mr. Wong and any other person pursuant to which he was appointed Chief Accounting Officer and there are no family
relationships between Mr. Wong and any of the Company’s directors or executive officers. Mr. Wong does not have a direct or indirect
material interest in any transaction that would be required to be disclosed under Item 404(a) of Regulation S-K.
The Company and Mr. Wong entered
into an Offer Letter establishing the terms of Mr. Wong’s employment with the Company (the “Offer Letter”), which provides
for the following compensation:
● An
annual base salary of $360,000
● Eligibility to earn a discretionary bonus with a target opportunity equal to 30% of his base salary paid
in either cash or equity, prorated for 2026;
● A sign-on bonus of $20,000, subject to continued employment through March 31, 2027; and
● A stock option award to purchase 25,000 shares of the Company’s common stock, effective as of the
Commencement Date, which award will vest 25% on the first anniversary of the Commencement Date and thereafter in thirty-six monthly increments,
subject to continued service to the Company on each vesting date and subject to the standard terms and conditions of the Company’s
form of stock option agreement.
Mr. Wong will also be eligible
to participate in the compensation and benefit programs generally available to executives of the Company, including participation in the
Company’s Executive Change in Control and Severance Plan.
The above description of the Offer Letter is qualified
in its entirety by reference to the terms of the Offer Letter, a copy of which is attached hereto as Exhibit 10.1 and is incorporated
herein by reference.